Cue Biopharma (NASDAQ:CUE) Stock Rating Lowered by Wall Street Zen

Cue Biopharma (NASDAQ:CUE) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a report on Thursday, August 13th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cue Biopharma currently has an average rating of “Sell”.

Cue Biopharma Stock Down 3.3%

Shares of Cue Biopharma stock opened at $23.18 on Friday. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $45.50. The firm has a market capitalization of $168.29 million, a PE ratio of -0.86 and a beta of 2.47. The stock’s fifty day moving average is $29.23 and its 200-day moving average is $133.59.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The company had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%.

Insider Transactions at Cue Biopharma

In other Cue Biopharma news, VP Michael Vincent Meluzio sold 5,628 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $169,346.52. Following the transaction, the vice president directly owned 48,961 shares of the company’s stock, valued at $1,473,236.49. This represents a 10.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Shao-Lee Lin sold 40,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00. Following the transaction, the chief executive officer directly owned 724,253 shares in the company, valued at approximately $19,627,256.30. This represents a 5.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 72,715 shares of company stock worth $2,041,555 in the last 90 days. 14.56% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Texas Capital Bank Wealth Management Services Inc bought a new position in Cue Biopharma in the second quarter worth $722,000. Persistent Asset Partners Ltd bought a new stake in Cue Biopharma in the 2nd quarter valued at $389,000. GC Wealth Management RIA LLC raised its stake in shares of Cue Biopharma by 35.0% in the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after buying an additional 1,200,000 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Cue Biopharma in the 2nd quarter valued at $219,000. Finally, BlackRock Inc. bought a new position in shares of Cue Biopharma during the 2nd quarter worth about $1,824,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.